-->

Zacks Rank Buy Alert

Post a Comment
Zacks | Our Research. Your Success.

Buy This Stock Before Earnings Are Reported

Zacks Member,

I added a stock to our private Surprise Trader portfolio today, and I wanted to let you know about it.

In addition to its rating as a Zacks Rank #2 (Buy), this Biotech stock boasts a Value Style Score of B, Growth of A, and Momentum of B, rounding out with an impressive VGM Composite Score of A.

This isn't your average Biotech. The stock has been delivering revenue growth and double-digit earnings growth. Plus, it's trading at just 11.4x earnings. That's about half of the S&P 500's 21.7x, and a start contrast to the industry average which is negative.

You'll want to see this time-sensitive recommendation before it reports earnings on Friday, May 9th—before Wall Street reacts to a positive earnings surprise and potentially drives up the stock price.

Here are three reasons you should take advantage:

1.It costs only $1 to see this pick and follow our Surprise Trader stocks for the next 30 days. During this time, you also get access to all Zacks private trading and investing services. No reason to hesitate. There's not a cent of further obligation.
2.This breakthrough strategy has an unprecedented 80% success rate for tipping off members to positive earnings surprises BEFORE their earnings reports are released and BEFORE other investors swarm in and drive up their prices.
3.It targets quick double-digit gains. While we can't guarantee 100% success, recent picks were closed for gains of +49.8%, +37.0% and +28.5% in as little as 4 days.¹

Remember it's crucial to buy shares of our Surprise Trader stock before the market opens on Friday, May 9 as earnings are scheduled to be reported that morning.

All the Best,

David Bartosiak - signature
David Bartosiak
Editor of Zacks Surprise Trader

Related Posts

There is no other posts in this category.

Post a Comment

Subscribe Our Newsletter